World Stem Cell Summit Poster Forum Prizes Sponsor

SAN DIEGO, CALIF., Oct. 10, 2013 (GLOBE NEWSWIRE) -- Genetics Policy Institute (GPI), producer of the annual World Stem Cell Summit, and Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and clinical development, announced today that Stemedica will serve as the exclusive sponsor of the Poster Forum at the 2013 World Stem Cell Summit, December 4-6, at the Manchester Grand Hyatt San Diego. As part of its sponsorship, Stemedica has contributed $5,000 in prize money to winning posters.

Bernard Siegel, executive director of the Genetics Policy Institute (GPI) and founder and co-chair of the Summit said, "The World Stem Cell Summit is a mission-driven event uniting the global stem cell community to chart the future of regenerative medicine. The annual Poster Forum aims at presenting cutting-edge research and original ideas to move the field forward to accelerate cures. Stemedica's sponsorship of the Poster Forum evidences its commitment to growing the entire field by supporting innovation and responsible research."

"We are honored to again be associated with the World Stem Cell Summit, one of the most important meetings for the stem cell community," stated Maynard Howe, Ph.D., CEO and Vice Chairman of Stemedica. "We are committed to supporting innovation, and through Stemedica's sponsorship of the Summit and the Poster Forum prizes, we believe we can inspire novel solutions by engaging the best and brightest minds from all the disciplines touching regenerative medicine." According to Nikolai Tankovich, M.D., Ph.D., President and Chief Medical Officer of Stemedica, "This collaboration between Stemedica and the World Stem Cell Summit creates a wonderful opportunity for our company to connect with the leaders of the global stem cell community and our current and future customers. We are grateful to have this valuable platform for progress in San Diego in 2013."

The World Stem Cell Summit Poster Forum is the only interdisciplinary stem cell poster session covering all topics in regenerative medicine. Posters display today's most innovative science, leading-edge technologies, industry updates, and regulatory solutions.  Attendees are welcome to submit posters in all areas of science, medicine, business, finance, regulation and law, ethics, policy, communications, and other topics related to the societal impact of stem cell research and the regenerative medicine field. Abstracts must be submitted by November 15, 2013. For topic suggestions and more information, visit http://worldstemcellsummit.com/poster-forum-information .
 
ABOUT THE WORLD STEM CELL SUMMIT: The World Stem Cell Summit is the flagship meeting of the international stem cell community. The Summit aims to accelerate the discovery and development of lifesaving cures and therapies, bringing global stakeholders together to solve global challenges. It builds a foundation to advance cell therapies by establishing a supportive environment of regulation, legislation, financing, reimbursement and patient advocacy. The 2013 World Stem Cell Summit will be held at the Manchester Grand Hyatt San Diego, in San Diego, California, December 4-6, 2013. It is presented by GPI and is co-organized by the California Institute for Regenerative Medicine, Mayo Clinic, Scripps Research Institute, Sanford-Burnham Medical Research Institute, and Kyoto University Institute for Integrated Cell-Material Sciences (iCeMS). For more information, visit  www.worldstemcellsummit.com .
 
ABOUT GPI: The Genetics Policy Institute (GPI) supports stem cell research to develop therapeutics and cures. GPI pursues its mission by producing the World Stem Cell Summit, honoring community leaders through the Stem Cell Action Awards, publishing the World Stem Cell Report, organizing educational initiatives and fostering strategic collaborations. For more information about GPI, visit www.genpol.org .
 
ABOUT STEMEDICA CELL TECHNOLOGIES, INC.: Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its Phase II clinical trials for ischemic stroke, acute myocardial infarct, and cutaneous photoaging. Stemedica is currently developing regulatory pathways for a number of other medical indications using adult allogeneic stem cells. The company is headquartered in San Diego, California.

A photo accompanying this release is available at: http://www.globenewswire.com/newsroom/prs/?pkgid=21471

GPI/WSCS13: Mara Leventhal at . Stemedica: Dave McGuigan at .